Predictive markers for ovarian cancer
Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.
1. A set of reagents to measure the levels of biomarkers in a specimen, wherein the biomarkers are selected from the group consisting of the following panels of biomarkers and their measurable fragments: (a) CA-125, CRP, EGF-R, CA-19-9, Apo-AI, Apo-CIII, IL-6, IL-18, MIP-1a, Tenascin C and Myoglobin; (b) CA-125, CRP, EGF-R, CA-19-9, Apo-AI, Apo-CIII, IL-6, MIP-1a, Tenascin C and Myoglobin; (c) CA19-9, CA125, CRP, and EGFR; (d) CA19-9, CA125, CRP, EGFR, ApoCIII, IL-18, and Myoglobin; (e) CA19-9, CA125, CRP, EGFR, IL-6, IL-18, and MIP1a; (f) CA19-9, CA125, CRP, EGFR, IL-18, MIP1a, and Myoglobin; (g) CA19-9, CA125, CRP, EGFR, ApoCIII, IL-18, and Myoglobin; (h) CA19-9, CA125, CRP, EGFR, IL-6, IL-18, and Myoglobin; (i) CA19-9, CA125, CRP, EGFR, ApoA1, MIP1a, and Myoglobin; (j) CA19-9, CA125, CRP, EGFR, ApoCIII, MIP1a, and Myoglobin; and (k) CA19-9, CA125, CRP, EGFR, ApoCIII, IL-6, and MIP1a, the set of reagents having a sensitivity and specificity of about 85% in a population that is symptomatic for ovarian cancer.
2. The set of reagents of claim 1 , wherein one or more of the biomarkers may be replaced by a molecule, or a measurable fragment of the molecule, found upstream or downstream of the biomarker in a biological pathway.
3. The set of reagents of claim 1 , wherein the reagents are binding molecules.
4. The set of reagents of claim 3 , wherein the binding molecules are antibodies.
5. A test kit comprising the set of reagents of claim 1 .
6. A multianalyte panel assay kit comprising the set of reagents of claim 1 .
7. A set of reagents to measure the levels of three or more biomarkers in a specimen, wherein the biomarkers comprise CA125, CRP and CA-19-9 and their measurable fragments, said set of reagents having a sensitivity and specificity of about 85% in a population that is symptomatic for ovarian cancer.
8. The set of reagents of claim 7 , wherein the biomarkers further comprise EGF-R and its measurable fragments.
9. The set of reagents of claim 7 , wherein one or more of the three or more biomarkers may be replaced by a molecule, or a measurable fragment of the molecule, found upstream or downstream of the biomarker in a biological pathway.
10. The set of reagents of claim 7 , wherein the reagents are binding molecules.
11. The set of reagents of claim 10 , wherein the binding molecules are antibodies.
12. A test kit comprising the set of reagents of claim 7 .
13. A multianalyte panel assay kit comprising the set of reagents of claim 7 .
14. The multianalyte panel assay kit of claim 13 , further comprising written instructions for performing an evaluation of biomarkers to predict the likelihood of ovarian cancer in a subject.
15. The test kit of claim 12 , further comprising written instructions for performing an evaluation of biomarkers to predict the likelihood of ovarian cancer in a subject.
16. A set of reagents to measure the levels of three or more biomarkers in a specimen, wherein the biomarkers comprise CA125, CRP and EGF-R and their measurable fragments, said set of reagents having a sensitivity and specificity of about 85% in a population that is symptomatic for ovarian cancer.
17. The set of reagents of claim 16 , wherein one or more of the biomarkers may be replaced by a molecule, or a measurable fragment of the molecule, found upstream or downstream of the biomarker in a biological pathway.
18. The set of reagents of claim 16 , wherein the reagents are binding molecules.
19. The set of reagents of claim 17 , wherein the binding molecules are antibodies.
20. A test kit comprising the set of reagents of claim 16 .
21. The test kit of claim 20 , further comprising written instructions for performing an evaluation of biomarkers to predict the likelihood of ovarian cancer in a subject.
22. A multianalyte panel assay kit comprising the set of reagents of claim 16 .
23. The multianalyte panel assay kit of claim 22 , further comprising written instructions for performing an evaluation of biomarkers to predict the likelihood of ovarian cancer in a subject.